Evidence map›Paper›PMID 40647508›Full record

ArticleCancers2025

Expression Profiles of Co-Inhibitory Receptors in Non-Urothelial Bladder Cancer: Preclinical Evidence for the Next Generation of Immune Checkpoint Inhibitors.

Severin Rodler, Stephan T Ledderose, Raphaela Waidelich, Jakob Kohler, Andrea Sendelhofert, Jozefina Casuscelli, Gerald Schulz, Christian G Stief, Lennert Eismann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Severin RodlerDepartment of Urology, University Hospital of Ludwig-Maximilian-University, 81377 Munich, Germany.
Stephan T LedderoseInstitute of Pathology, Ludwig-Maximilian-University, 80337 Munich, Germany.ORCID 0000-0001-7313-2088
Raphaela WaidelichDepartment of Urology, University Hospital of Ludwig-Maximilian-University, 81377 Munich, Germany.
Jakob KohlerDepartment of Urology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.ORCID 0009-0001-8972-2290
Andrea SendelhofertInstitute of Pathology, Ludwig-Maximilian-University, 80337 Munich, Germany.
Jozefina CasuscelliDepartment of Urology, University Hospital of Ludwig-Maximilian-University, 81377 Munich, Germany.ORCID 0000-0002-9899-1986
Gerald SchulzDepartment of Urology, University Hospital of Ludwig-Maximilian-University, 81377 Munich, Germany.ORCID 0000-0002-0340-0304
Christian G StiefDepartment of Urology, University Hospital of Ludwig-Maximilian-University, 81377 Munich, Germany.ORCID 0000-0003-3291-9460
Lennert EismannDepartment of Urology, University Hospital of Ludwig-Maximilian-University, 81377 Munich, Germany.ORCID 0000-0002-9971-4411

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibition is a cornerstone of bladder cancer therapy, but its efficacy in non-urothelial subtypes of bladder cancer is limited, and the prognosis remains poor. Therefore, we investigated the potential of the immune checkpoint molecules TIM-3, TIGIT, and LAG-3 in squamous-cell carcinoma (SCC) and adenocarcinoma (ADENO) of the urinary bladder. Tumor-infiltrating lymphocytes (TILs) showed a high expression of TIM-3 and TIGIT in both SCC and ADENO, while LAG-3-positive TILs were absent in ADENO and present in 46% of SCC. Quantitative analysis revealed age-independent expression of TIM-3 in SCC (r = -0.001,

Indexed as

adenocarcinomabladder cancercoinhibitory receptorLAG-3squamous-cell carcinomaTIGITTIM-3variant histology

Identifiers

PMID40647508
PMCPMC12248772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.